{"id":643,"date":"2013-05-27T13:58:01","date_gmt":"2013-05-27T13:58:01","guid":{"rendered":"http:\/\/iatdmct.com\/?page_id=643"},"modified":"2013-09-05T11:11:06","modified_gmt":"2013-09-05T11:11:06","slug":"oral-presentations","status":"publish","type":"page","link":"http:\/\/iatdmct.com\/?page_id=643","title":{"rendered":"Oral Presentations"},"content":{"rendered":"

1400-1500 MONDAY AFTERNOON<\/span><\/p>\n

EFFECT OF THE CYP3A5 6986A>G POLYMORPHISM ON TACROLIMUS PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS: A META-ANALYSIS<\/span>
\nBuendia JA1<\/sup>, Bramuglia G2<\/sup>,Staatz CE3<\/sup>. 1<\/sup>Pharmacology and Toxicology Department. Faculty of Medicine. University of Antioquia, Colombia. Email: Jefferson.buendia@gmail.com<\/a>. 2<\/sup>Faculty of Pharmacy and Biochemistry. University of Buenos Aires, Argentina. Email: gfbramuglia@gmail.com<\/a>. 3<\/sup>School of Pharmacy, University of Queensland. Australia. Email:chris@pharmacy.uq.edu.au<\/a>.
\n
\nIMPACT OF CYP3A4*22 <\/em>ALLELE ON TACROLIMUS PHARMACOKINETICS IN EARLY PERIOD AFTER RENAL TRANSPLANTATION: TOWARDS UPDATED GENOTYPE-BASED DOSING GUIDELINES.<\/span>
\nElens Laure<\/span>1,2<\/sup>, Capron Arnaud1,3<\/sup>, van Schaik Ron HN2<\/sup>, Wallemacq Pierre1,3<\/sup>, Michel Mourad4<\/sup>, Vincent Haufroid1,3<\/sup>. 1<\/sup>Louvain centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Exp\u00e9rimentale et Clinique (IREC), Universit\u00e9 catholique de Louvain , Brussels, Belgium; 2<\/sup>Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands; 3<\/sup>Laboratory of Analytical Biochemistry, Cliniques universitaires St Luc, , Universit\u00e9 catholique de Louvain, Brussels, Belgium; 4<\/sup>Surgery and Abdominal Transplantation Division, Cliniques universitaires St Luc, Universit\u00e9 catholique de Louvain, Brussels, Belgium.
\n
\nINFLUENCE OF CYP3A4, CYP3A5 AND MDR1-C3435T GENETIC POLYMORPHISMS IN TACROLIMUS PHARMACOKINETICS IN ADULT RENAL TRANSPLANT PATIENTS<\/span>
\nSalvador-Garrido P<\/span>, Outeda-Mac\u00edas M, Seoane-Pillado MT, Pedreira-V\u00e1zquez I, Mart\u00edn-Herranz I. Pharmacy Service. University Hospital of A Coru\u00f1a. Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a. A Coru\u00f1a. Spain.<\/span>
\n
\nINTERACTION BETWEEN TACROLIMUS AND NICARDIPINE IN A PEDIATRIC RENAL TRANSPLANT WITH CYTOCHROME P450 3A LOSS-OF-FUNCTION GENOTYPES<\/span>
\nPROMIS AS1<\/sup>, FROGER C1<\/sup>, LAROCHE ML1<\/sup>, SAINT-MARCOUX F1<\/sup>, SALAS C2<\/sup>, GUIGONIS V2<\/sup>, WOILLARD JB1<\/sup>, MARQUET P1<\/sup>, PICARD N<\/span>1<\/sup>. 1<\/sup>CHU Limoges, Department of Pharmacology, Toxicology and Pharmacovigilance, Limoges, France (the two first authors contributed equally to this work); 2<\/sup>CHU Limoges, Department of paediatrics, Mother & Child Hospital, Limoges, France.<\/span>
\n
\nEFFECT OF THE CYP3A5 GENOTYPE OF RECIPIENTS AND DONORS ON TACROLIMUS PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS.<\/span>
\nJefferson Antonio Buend\u00eda1<\/sup>, Esteban Otamendi3<\/sup>, Fernando Cairo3<\/sup>, Andres Ruf3<\/sup>, Maria de Davila3<\/sup>, Paula Schaiquevich2<\/sup>, Yanina Powazniak4<\/sup>, Julieta Nafissi4<\/sup>, Alberto Lazarowski2<\/sup>, Guillermo Bramuglia2,4<\/sup> and Federico Villamil3<\/sup>. 1<\/sup>Pharmacology and Toxicology Department. Faculty of Medicine. University of Antioquia, Colombia. 2<\/sup>Faculty of Pharmacy and Biochemistry. University of Buenos Aires, Argentina. 3<\/sup>CIPREC, Buenos Aires, Argentina. 4<\/sup>Fundacion Investigar, Buenos Aires. Argentina.<\/span>
\n
\nPREDICTION OF THE HEMATOCRIT OF DRIED BLOOD SPOTS VIA POTASSIUM MEASUREMENT ON A ROUTINE CLINICAL CHEMISTRY ANALYZER<\/span>
\nCapiau S1<\/sup>, Stove VV2<\/sup>, Lambert WE1<\/sup>, Stove CP<\/span>1<\/sup>. 1<\/sup>Laboratory of Toxicology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium; 2<\/sup>Department of Clinical Chemistry, Ghent University Hospital, Ghent, Belgium; E-mail:christophe.stove@ugent.be<\/a>.
\n
\nDEVELOPMENT AND CLINICAL EVALUATION OF A DRIED URINE SPOT METHOD FOR DETERMINATION OF HIPPURIC ACID AND CREATININE.<\/span>
\nAntunes MV, Niederauer C, Linden R<\/span>. Universidade Feevale, Novo Hamburgo \u2013 RS, Brazil.<\/span>
\n
\nDRIED BLOOD SPOTS AS AN ALTERNATIVE SAMPLING STRATEGY FOR CYP1A2 PHENOTYPING.<\/span>
\nDe Kesel PMM<\/span>, Lambert WE, Stove CP. Laboratory of Toxicology, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium. Email:pieter.dekesel@ugent.be<\/a>.<\/span>
\n
\nDETERMINATION OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE IN DRIED BLOOD SPOTS USING LC-MS\/MS.<\/span>
\nE.J.J. Berm<\/span>1<\/sup>, E. Brummel-Mulder2<\/sup>, J. Paardekooper2<\/sup>, E. Hak3<\/sup>, B. Wilffert1<\/sup>, J.G. Maring2<\/sup>. 1<\/sup>Department of Pharmacy, section Pharmacotherapy and Pharmaceutical Care , University of Groningen, the Netherlands. 2<\/sup>Laboratory for Drug Analysis &Toxicology, Diaconessen Hospital Meppel& Bethesda Hospital Hoogeveen, the Netherlands. 3<\/sup>Deptartment of Pharmacy, section PharmacoEpidemiology and PharmacoEconomics, University of Groningen, the Netherlands.<\/span>
\n
\nANALYSIS OF ATYPICAL ANTIPSYCHOTICS: COMPARISON OF DRIED BLOOD SPOT CARDS.<\/span>
\nFisher DS<\/span>, Partridge SJ, Flanagan RJ. Toxicology Unit, King\u2019s College Hospital, London, UK.<\/span>
\n
\nRESOLUTION OF INTERFERENCES IN DEVELOPMENT AND CLINICAL VALIDATION OF A TURBULENT-FLOW LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRIC METHOD FOR POSACONAZOLE AND VORICONAZOLE IN SERUM<\/span>
\nSchofield.R1<\/sup>, Breaud.A2<\/sup>, Clarke.W2<\/sup>, Bechtel.L<\/span>3<\/sup>. 1<\/sup>Chemistry Service, Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. 2<\/sup>Department of Pathology, the Johns Hopkins Hospital, Baltimore, MD. 3<\/sup>Forensic Laboratories, Denver, CO.
\n
\nMONITORING OF AMPHOTERICIN B IN HUMAN PLASMA AND CSF BY HPLC: A CASE REPORT.<\/span>
\nLiu S\uff0cDai Q. Department of Pharmacy, Southwest Hospital, Third Military Medical University, Chongqing\uff0cChina.
\n
\nA PRACTICAL THRICE WEEKLY ERTAPENEM DOSAGE REGIME FOR CHRONIC HEMODIALYSIS PATIENTS.<\/span>
\nBosma M1<\/sup>,*,de Man P1,2<\/sup>, Rietveld A1,3<\/sup>, Touw D5<\/sup>, Geerlings C.1,4<\/sup>. 1<\/sup>Sint Franciscus Gasthuis, Rotterdam, The Netherlands. 2<\/sup>Department of microbiology. 3<\/sup>Department of Nephrology, 4<\/sup>Hospital Pharmacy. 5<\/sup>Hospital Pharmacy, Apotheek Haagse Ziekenhuizen, Den Haag, The Netherlands. *Presently no affiliation
\n
\nTHERAPEUTIC DRUG MONITORING GUIDED EXTENDED AMINOGLYCOSIDES DOSING REGIMEN IN PAEDIATRIC CYSTIC FIBROSIS (CF) PATIENTS: A STEP FOREWARD.<\/span>
\nTesfaye H1<\/sup>, Jedlickova B1<\/sup>, Prusa R1<\/sup>, Bartosova J2<\/sup>, Kucerova T2<\/sup>, Skalicka V2<\/sup>. Kreslova M3<\/sup>. 1<\/sup>Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology. 2<\/sup>Department of Paediatrics, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic. 3<\/sup>Department of Paediatrics, Faculty Hospital in Plzen, Czech Republic.<\/span>
\n
\nSIMULTANEOUS QUANTIFICATION OF 17 ANTIBIOTICS IN HUMAN PLASMA USING LC-MS\/MS FOR ROUTINE BASIS TDM.<\/span>
\nWoloch C, Dupuy C, Lefeuvre S, Poinsignon V, Gutmann L and Billaud EM<\/span>. CHU Paris Ouest – HEGP, Paris Descartes University, Pharmacology, Microbiology, 75015 Paris, France. <\/span>
\n
\n1600-1700 MONDAY AFTERNOON<\/span>
\n
\nDETECTION OF 57 DRUGS AND METABOLITES IN MECONIUM BY LIQUID CHROMATOGRAPHY-TIME OF FLIGHT MASS SPECTROMETRY.<\/span>
\nRasmussen, N.N.<\/span>1<\/sup>, Marin, S.J.2<\/sup>, Clark, C.J.1<\/sup>, McMillin, G.A.2,3<\/sup>. 1<\/sup>ARUP Laboratories, Salt Lake City, UT. 2<\/sup>ARUP Institute for Experimental and Clinical Pathology, Salt Lake City, UT. 3<\/sup>University of Utah Department of Pathology, Salt Lake City, UT. <\/span>
\n
\nDEVELOPMENT OF A QUALITATIVE URINE DRUG PANEL BY LIQUID CHROMATOGRAPHY TIME OF FLIGHT MASS SPECTROMETRY (LC-TOF-MS)<\/span>
\nLawlor B.G.<\/span>1<\/sup>, Marin S.J.2<\/sup>, Chittamma A.2<\/sup>, Clark C.J.1<\/sup>, McMillin G.A.1,3<\/sup>. 1<\/sup>ARUP Laboratories, Inc., Salt Lake City, UT; 2<\/sup>ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 3<\/sup>Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.<\/span>
\n
\nDEVELOPMENT OF A HIGH RESOLUTION MASS SPECTROMETRY METHOD FOR URINE DRUG SCREENING.<\/span>
\nThoren KL<\/span>, Lynch KL, Shugarts SB, Wu AHB. Department of Laboratory Medicine, University of California San Francisco and San Francisco General Hospital, CA 94110.<\/span>
\n
\nSTUDIES ON THE METABOLISM AND THE DETECTABILITY OF CAMFETAMINE IN RAT URINE USING GC-MS AND LC-(HR)-MSn<\/sup> TECHNIQUES.<\/span>
\nWelter J<\/span>1<\/sup>, Kavanagh P2<\/sup>, and Maurer HH1<\/sup>. 1<\/sup>Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany. 2<\/sup>Department of Pharmacology and Therapeutics, St. James\u2019s Hospital, Dublin, Ireland.
\n
\nDETECTION OF in utero <\/em>MARIJUANA EXPOSURE BY THREE METHODS USING UMBILICAL CORD TISSUE.<\/span>
\nWilliams J.A.<\/span>1<\/sup>, Marin S.J.2<\/sup>, Chittamma A.1<\/sup>, Clark, C.1<\/sup>, McMillin G.A.1,3<\/sup>. 1<\/sup>ARUP Laboratories, Inc., Salt Lake City, UT. 2<\/sup>ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. 3<\/sup>Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.
\n
\nRELATIONSHIP BETWEEN DRUG-DRUG INTERACTIONS, MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2 (MRP2) FUNCTION AND METHOTREXATE CLEARANCE IN ADULTS WITH LYMPHOID MALIGNANCIES.<\/span>
\nBenz-de Bretagne I.<\/span>1<\/sup>, Le Gouge A.2<\/sup>, Zahr N.3<\/sup>, Hulot J.S.3<\/sup>, Leblond V.4<\/sup>, Hoang-Xuan K.5<\/sup>, Gyan E.6<\/sup>, Lissandre S.6<\/sup>, Choquet S.4<\/sup>, Le Guellec C.1<\/sup>. 1<\/sup>Laboratory of Biochemistry and Molecular Biology, CHU of Tours, Fran\u00e7ois Rabelais University, PRES Centre Val de Loire Universit\u00e9, EA4245, Tours, France; 2<\/sup>Clinical Investigation Center, Inserm 202, Tours, France ; 3<\/sup>Pharmacology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France ; 4<\/sup>Hematology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France ; 4<\/sup>Neurology Department, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France ; 6<\/sup>Hematology and Cellular Therapy, CHU of Tours, Tours, France.<\/span>
\n
\nCLINICAL PHARMACOKINETICS OF DORIPENEM AND MEROPENEM IN PROSTATE TISSUE, AND DOSING CONSIDERATIONS FOR PROSTATITIS BASED ON SITE-SPECIFIC PHARMACODYNAMIC TARGET ATTAINMENT.<\/span>
\nIkawa K<\/span>1<\/sup>, Nakamura K2<\/sup>, Nishikawa G2<\/sup>, Yamada Y3<\/sup>, Zennami K2<\/sup>, Mitsui K4<\/sup>, Narushima M5<\/sup>, Ikeda K1<\/sup>, Morikawa N1<\/sup>, Sumitomo M2<\/sup>. 1<\/sup>Department of Clinical Pharmacotherapy, Hiroshima University, Hiroshima; 2<\/sup>Department of Urology, Aichi Medical University School of Medicine, Aichi; 3<\/sup>Department of Urology, Gifu Social Insurance Hospital, Gifu; 4<\/sup>Department of Urology, Tokoname Municipal Hospital, Aichi; 5<\/sup>Department of Urology, Meitetsu Hospital, Aichi, Japan.<\/span>
\n
\nAN EXTERNAL EVALUATION OF VANCOMYCIN PHARMACOKINETICS AMONG SEPTIC NEONATES.<\/span>
\nBhongsatiern, J.<\/span>1,2<\/sup>, Sherwin, C.M.T.1<\/sup>, Stockmann, C.1<\/sup> Yu, T.1<\/sup>, Reith, D.M.3<\/sup>, Desai, P.B.2<\/sup>, Spigarelli, M.G.1<\/sup>. 1<\/sup>Department of Pediatrics, Div. of Clinical Pharmacology, University of Utah. 2<\/sup>James L. Winkle College of Pharmacy, University of Cincinnati. 3<\/sup>Dept. of Women\u2019s and Children\u2019s Health, University of Otago, Dunedin, New Zealand.<\/span>
\n
\nTHE NEXT GENERATION PHARMACOKINETIC SOFTWARE SUITE, Edsim++ AND MwPharm++, PROVIDE CLINICIANS THE MEANS TO DEVELOP AND USE PK\/PD MODELS IN A CLINICAL SETTING.<\/span>
\nPot\u016f\u010dek J., Dou\u0161a J.<\/span>, Punt N1<\/sup>. Mediware a.s. Evropsk\u00e1 655\/116, 160 00 Praha 6, Czech republic. 1<\/sup>Medimatics, Praaglaan 131, 6229 HR, Maastricht, The Netherlands.<\/span>
\n
\nMODELING OF THE EXPOSURE TO TACROLIMUS IN KIDNEY TRANSPLANTATION.<\/span>
\nBen Fredj N.1<\/sup>, Woillard J.B.2<\/sup>, Debord J.2<\/sup>, Chaabane A.1<\/sup>, Chadly Z.1<\/sup>, Ben Fadhel N.1<\/sup>, Boughattas N.1<\/sup>, Marquet P.2<\/sup>, Saint-marcoux F.2<\/sup>, Aouam K<\/span>1<\/sup>. 1<\/sup>Department of Pharmacology, Monastir, Tunisia. 2<\/sup>Department of Pharmacology, Limoges University Hospital, France.<\/span>
\n
\nPHARMACOKINETIC\/PHARMACODYNAMIC (PK\/PD) MONITORING OF MYCOPHENOLATE MOFETIL IN de novo AND LONG-TERM RENAL TRANSPLANT PATIENTS.<\/span>
\n Molinaro M<\/span>1<\/sup>, Chiarelli L.R2<\/sup>, Segoloni G.P3<\/sup>, Libetta C4<\/sup>, Dal Canton A4<\/sup>, Regazzi M1<\/sup>. 1<\/sup>Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico S.Matteo – Pavia; 2<\/sup>Department of Biology and Biotechnology, University of Pavia; 3<\/sup>Division of Nephrology, Dialysis and Transplantation, San Giovanni Battista Hospital – Torino; 4<\/sup>Unit of Nephrology, Dialysis and Transplantation, Fondazione IRCCS Policlinico S.Matteo \u2013 Pavia, (Italy).
\n
\nDYNAMIC CHARACTERISTICS OF IMMUNE REGULATORY STATE IN ALLO-LIVER RECIPIENTS WITH TACROLIMUS-BASED REGIMEN.<\/span>
\nBei Cai1<\/sup>, Yi Li1<\/sup>, Yangjuan Bai1<\/sup>, Yuangao Zou1<\/sup>, Lvnan Yan2<\/sup>, Lanlan Wang1<\/sup>*. 1<\/sup>Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. 2<\/sup>Center of Liver Transplantation, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China. *Corresponding author, e-mail: wanglanlan999@163.com<\/a>.
\n
\nSIROLIMUS AND EVEROLIMUS IMMUNOASSAY CROSS-REACTIVITY IN A PATIENT WITH TUBEROUS SCLEROSIS.<\/span>
\nKieffer TW, Zimmerman MK<\/span>. Indiana University School of Medicine, Indianapolis, IN.<\/span>
\n
\nEVEROLIMUS QMS ASSAY BY USING THERMOFISHER INDIKO, BECKMAN DXc AND AU680 ANALYZERS AND LIMITED COMPARISON TO LC-MS\/MS.<\/span>
\nK. Garrison1<\/sup>, K. L.Johnson-Davis2<\/sup>, S.H. Wong<\/span>3<\/sup>. 1<\/sup>Wake Forest Baptist Health, Winston-Salem, NC. 2<\/sup>ARUP and University of Utah, Salt Lake City, UT. 3<\/sup>Wake Forest School of Medicine, Winston-Salem, NC.
\n
\nSYSTEMATIC CONVERSION TO GENERIC TACROLIMUS IN STABLE KIDNEY TRANSPLANT PATIENTS.<\/sup>
\nRosenborg S<\/span>1,2<\/sup>, Nordstr\u00f6m A1<\/sup>, Almquist T3<\/sup>, Wennberg L4<\/sup>, B\u00e1r\u00e1ny P2<\/sup>. Clinics of 1<\/sup>Clinical Pharmacology, 2<\/sup>Nephrology and 3<\/sup>Transplantation Surgery, Karolinska University Hospital, and 4<\/sup>Nephrology at Danderyd\u2019s Hospital, Stockholm, Sweden.
\n
\n1400-1500 WEDNESDAY AFTERNOON<\/span>
\n
\nCD26 EXPRESSION ON T-CELLS AND DIPETIDYL PEPTIDASE IV (DPPIV) ACTIVITY IN PLASMA AS A COMPLEMENTARY TOOL TO THERAPEUTIC DRUG MONITORING (TDM) IN STABLE KIDNEY TRANSPLANT (KTx) PATIENTS. <\/span>
\nShipkova M<\/span>, Strobel S, Leicht S, Bolley R, Wilhlem J, Wollmeyer J, Klett, C, Olbricht C, Wieland E. Klinikum Stuttgart, Stuttgart. Germany.<\/span>
\n
\nNFAT-REGULATED CYTOKINE EXPRESSION DURING TACROLIMUS THERAPY EARLY AFTER TRANSPLANTATION.<\/span>
\nBremer S<\/span>1<\/sup>, Johansson ED1,2<\/sup>, Pham L1,2<\/sup> Vethe NT3<\/sup> Line P-D4<\/sup> Midtvedt K5<\/sup> Skauby M4<\/sup> Hole K2,3<\/sup>, Berg C2,3<\/sup>, Bergan S2,3<\/sup>. 1<\/sup>Department of Medical Biochemistry, Oslo University Hospital, Norway. 2<\/sup>School of Pharmacy, University of Oslo, Norway. 3<\/sup>Dept. of Pharmacology, Oslo University Hospital, Norway. 4<\/sup>Department of Transplantation, Oslo University Hospital, Norway. 5<\/sup>Department of Transplant Medicine, Oslo University Hospital, Norway.<\/span>
\n
\nIFN-&#947, IL-17 AND IL-2 AS PREDICTIVE BIOMARKERS OF ACUTE REJECTION IN LIVER AND KIDNEY TRANSPLANTATION: RESULTS OF A MULTICENTER STUDY.<\/span>
\nO. Mill\u00e1n1,2<\/sup>, L. Rafael-Valdivia3<\/sup>, D. San Segundo4<\/sup>, F. Boix5<\/sup>, MJ. Castro-Panete6<\/sup>, M. L\u00f3pez-Hoyos4<\/sup>, M. Muro5<\/sup>, D. Valero-Herv\u00e1s6<\/sup>, A. Rimola2,3<\/sup>, M. Navasab3<\/sup>, MA. De Cos7<\/sup>, M. Miras8<\/sup>, A. Andr\u00e9s9<\/sup>, L. Guirado10<\/sup>, J. Pascual11<\/sup>, M. Bruneta*. 1<\/sup>Farmacolog\u00eda y Toxicolog\u00eda, Centro de Diagn\u00f3stico Biom\u00e9dico, IDIBAPS, Hospital Cl\u00ednico, Universidad de Barcelona, Barcelona, Spain. 2<\/sup>Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Spain. 3<\/sup>Unidad de H\u00edgado, Hospital Cl\u00ednico, IDIBAPS, Barcelona, Spain. 4<\/sup>Servicio de Inmunolog\u00eda, Hospital Universitario Marqu\u00e9s de Valdecilla-IFIMAV, Santander, Spain. 5<\/sup>Servicio de Inmunolog\u00eda, Hospital Universitario Virgen Arrixaca, Murcia, Spain. 6<\/sup>Servicio de Inmunolog\u00eda, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. 7<\/sup>Farmacolog\u00eda Cl\u00ednica, Hospital Universitario Marqu\u00e9s de Valdecilla-IFIMAV, Santander, Spain. 8<\/sup>Servicio de Medicina Digestiva Hospital Universitario Virgen Arrixaca, Murcia, Spain. 9<\/sup>Servicio de Nefrolog\u00eda, Hospital Universitario 12 de Octubre. Universidad Complutense. Madrid, Spain. 10<\/sup>Unidad de Trasplante Renal, Servico de Nefrologia, Fundaci\u00f3 Puigvert, Barcelona, Spain. 11<\/sup>Servicio de Nefrolog\u00eda, Hospital del Mar, Barcelona, Spain.
\n
\nIMPDH ACTIVITY IN ex vivo<\/em>-STIMULATED LYMPHOCYTES AS A MARKER OF MYCOPHENOLIC ACID RESPONSE IN RENAL TRANSPLANT RECIPIENTS.<\/span>
\nVethe NT1<\/sup>, Hole K1,2<\/sup>, Berg C2,3<\/sup>, Bremer S3<\/sup>, Line P-D4<\/sup> Midtvedt K5<\/sup> Skauby M4<\/sup>, Andersen AM1<\/sup>, Dahl Johansson E2,3<\/sup>, Pham L2,3<\/sup>, Bergan S<\/span>1,2<\/sup>. 1<\/sup>Department of Pharmacology, Oslo University Hospital, Norway. 2<\/sup>School of Pharmacy, University of Oslo, Norway. 3<\/sup>Department of Medical Biochemistry, Oslo University Hospital, Norway. 4<\/sup>Department of Transplantation, Oslo University Hospital, Norway. 5<\/sup>Department of Transplant Medicine, Oslo University Hospital, Norway.
\n
\nEX-VIVO PHARMACODYNAMICS OF TACROLIMUS ON THE LYMPHOCYTE CALCINEURIN PATHWAY: THE INTEGRATION OF SIGNALS.<\/span>
\nNoceti O<\/span>1,2,3<\/sup>, Taupin J-L4<\/sup>, Boumediene A5<\/sup>, Esper\u00f3n P3<\/sup>, Gerona S2<\/sup>, Touri\u00f1o C6<\/sup>, Marquet P1<\/sup>. 1<\/sup>INSERM UMR-S850, Laboratory of Medical Pharmacology, France; University of Limoges, France; CHU Limoges, France. 2<\/sup>Centro Nacional Hepato- Biliopancre\u00e1tico, National Transplant Liver Center, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay. 3<\/sup>Molecular Biology Unit, Clinical Biochemistry Department, School of Chemistry, Universidad de la Republica, Montevideo, Uruguay. 4<\/sup>CNRS-UMR 5164, Victor Segalen University, Bordeaux, France. 5<\/sup>Laboratory of Immunology, University Hospital Center Dupuytren, Limoges, France. 6<\/sup>Department of Fundamental Medicine, School of Medicine, Universidad de la Republica, Montevideo, Uruguay.<\/span>
\n
\nASSESSMENT OF PASSIVE AND SYSTEMIC EXPOSURE TO DRUGS OF ABUSE IN CHILDREN THROUGH HAIR ANALYSIS.<\/span>
\nGareri J<\/span>1,2<\/sup>, Natekar A1<\/sup>, Walasek P1<\/sup>, Karaskov T1<\/sup>, Koren G1,2,3<\/sup>. 1<\/sup>Motherisk Laboratory, Hospital for Sick Children, Toronto, Canada; 2<\/sup>Department of Pharmaceutical Science, University of Toronto, Toronto, Canada; 3<\/sup>Ivey Chair in Molecular Toxicology, University of Western Ontario, London, Canada.
\n
\nNORCOCAINE AS A BIOMARKER IN HUMAN HAIR TO DIFFERENTIATE COCAINE USE FROM EXTERNAL EXPOSURE IN A HIGH-RISK POPULATION.<\/span>
\nPoon, S<\/span>1,2<\/sup>, Walasek, P1<\/sup>, Koren, G1,2<\/sup>. 1<\/sup>The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Canada; 2<\/sup>Department of Pharmacology &Toxicology, University of Toronto, Toronto, Canada.<\/span>
\n
\nPOLYDRUG USE AMONG PREGNANT METHADONE USERS.<\/span>
\nDelano, K.<\/span>, Gareri, J. and Koren, G. University of Toronto, Toronto, ON Canada; Department of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, ON Canada.>\/span>
\n
\nASSESSMENT OF ARSENIC TOXICITY USING A COMBINATION OF QUANTITATIVE SCREENING AND CHROMATOGRAPHIC SEPARATION WITH INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY.<\/span>
\nWise P.<\/span>1<\/sup>, Haglock C.J.2<\/sup>, Strathmann F.G.2,3<\/sup>. 1<\/sup>ARUP Laboratories, Salt Lake City, UT; 2<\/sup>ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 3<\/sup>University of Utah, Department of Pathology, Salt Lake City, UT.<\/span>
\n
\nA TOXICOKINETIC-TOXICODYNAMIC MODEL FOR PARAQUAT IN HUMANS.<\/span>
\nFlora T. Musuamba<\/span>1<\/sup>, Klintean Wunnapuk2,3<\/sup>, Fahim Mohammed4,5,6<\/sup>, Indika Gawarammana4,5,6<\/sup>, Rorger K. Verbeeck1,7<\/sup>, Nicholas A. Buckley6,8,9<\/sup>, Michael S. Roberts2,10<\/sup>, Pierre Wallemacq1<\/sup>. 1<\/sup>Louvain Drug Research Institute, Louvain Centre for Toxicology and Applied Pharmacology, Catholic University of Louvain, Brussels, Belgium. 2<\/sup>Therapeutics Research Centre, School of Medicine, University of Queensland, Brisbane, QLD, Australia. 3<\/sup>Department of Forensic Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. 4<\/sup>Department of Pharmacology, Faculty of Medicine, University of Ruhuna, Sri Lanka. 5<\/sup>Department of Medicine, Faculty of Medicine, University of Peradeniya, Sri Lanka. 6<\/sup>South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, University of Peradeniya, Sri Lanka. 7<\/sup>Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa. 8<\/sup>Australian National University, Canberra, Australia. 9<\/sup>Professorial Medicine Unit, University of New South Wales, NSW, Australia. 10<\/sup>School of Pharmacy & Medical Science, University of South Australia, Adelaide, SA, Australia.<\/span>
\n
\nTHE EFFECT OF GENETIC VARIATIONS IN CYTOCHROMES P450 3A, THE P450 OXYDOREDUCTASE (POR) AND THE NUCLEAR RECEPTOR PPARA ON SIROLIMUS in vitro<\/em> METABOLISM, TROUGH LEVELS AND ADVERSE EVENTS IN KIDNEY TRANSPLANT RECIPIENTS.<\/span>
\nWoillard JB<\/span>1,2,3<\/sup>, Kamar N4,5,6<\/sup>, Coste S2<\/sup>, Rostaing L4,5,6<\/sup>, Marquet P1,2,3<\/sup>, Picard N1,2,3<\/sup>. 1<\/sup>INSERM, UMR S-850, Limoges, France; 2<\/sup>Univ Limoges, Limoges, France; 3<\/sup>CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France; 4<\/sup>CHU Toulouse, Department of Nephrology-Dialysis and Multi-Organ Transplantation, Toulouse, France; 5<\/sup>INSERM, U563, IFR\u2013BMT, CHU Purpan, Toulouse, France; 6<\/sup>Univ Paul Sabatier, Toulouse, France.<\/span>
\n
\nEVALUATING THE EFFECT OF CYP3A4 AND CYP3A5 POLYMORPHISMS ON CYCLOSPORINE, EVEROLIMUS AND TACROLIMUS PHARMACOKINETICS IN RENAL TRANSPLANTATION PATIENTS.<\/span>
\nMoes D.J.A.R<\/span>1,2<\/sup>, Swen J.J.1<\/sup>, den Hartigh J1<\/sup>, van der Straaten T.1<\/sup>, Homan van der Heide J.J. Bemelman F., de Fijter J.W.2<\/sup> , Guchelaar H.J.1<\/sup>. 1<\/sup>Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands. 2<\/sup>Department of Nephrology, Leiden University Medical Center, Leiden, The Netherlands. 3<\/sup>Department of Nephrology, Academical Medical Center, Amsterdam, The Netherlands. 4<\/sup>Department of Nephrology, University Medical Centre Groningen, Groningen, The Netherlands.<\/span>
\n
\nTHE IMPACT OF CYP3A5*3 POLYMORPHISM ON SIROLIMUS PHARMACOKINETICS: NOVEL INSIGHTS FROM A PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING APPROACH<\/span>
\nEmoto C1<\/sup>, Fukuda T1,2<\/sup>, Venkatasubramanian R1,3<\/sup>, Cox S1<\/sup>, Christians U4<\/sup>, and Vinks A. A.1,2<\/sup>. 1<\/sup>Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center. 2<\/sup>Department of Pediatrics, University of Cincinnati College of Medicine. 3<\/sup>Department of Anesthesia, Cincinnati Children\u2019s Hospital Medical Center. 4<\/sup>iC42 Integrated Solutions in Clinical Research and Development, University of Colorado. <\/span>
\n
\nASSOCIATION BETWEEN INTRA-RENAL P-gp EXPRESSION AND CYCLOSPORINE CONCENTRATIONS IN RENAL TRANSPLANTATION.<\/span>
\nSallustio B<\/span>1,2<\/sup>, Noll B1<\/sup>, Coller J2<\/sup>, Somogyi A2<\/sup>. Department of Clinical Pharmacology, The Queen Elizabeth Hospital1<\/sup>, South Australia; Discipline of Pharmacology, University of Adelaide2<\/sup>, South Australia.<\/span>
\n
\nGENETIC VARIATIONS IN MEMBRANE TRANSPORTERS AND THE DECREASE IN NEUTROPHILS INDUCED BY GANCICLOVIR THERAPY: AN EXPLORATORY STUDY IN RENAL TRANSPLANT PATIENTS.<\/span>
\nBILLAT P-A.1<\/sup>, SAINT-MARCOUX F.1,2<\/sup>, WOILLARD J-B.1,2<\/sup> MERVILLE P.3<\/sup>, ROSTAING L.4<\/sup>, KAMAR N.4<\/sup>, REROLLE J-P.5<\/sup>, ESSIG M.1,5<\/sup>, MARQUET P.1,2<\/sup>, PICARD N.<\/span>1,2<\/sup>. 1<\/sup>Inserm UMR S-850, Laboratoire de Pharmacologie m\u00e9dicale, Facult\u00e9 de m\u00e9decine, Limoges – FRANCE. 2<\/sup>Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges – FRANCE. 3<\/sup> H\u00f4pital Pellegrin, CHU Bordeaux, Service de N\u00e9phrologie, Transplantation, Dialyse, Bordeaux – FRANCE. 4<\/sup>CHU Toulouse Rangueil, Service de N\u00e9phrologie, HTA, Dialyse et Transplantation d\u2019Organes, Toulouse – FRANCE. 5<\/sup>Service de N\u00e9phrologie, CHU Limoges, Limoges – FRANCE.
\n
\nA POTENTIAL FOR INDIVIDUALIZED DOSING OF PREDNISOLONE IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS.<\/span>
\nSkauby RH, Bjerre AK, S\u00e6ves I, Bergan S. Dept of Medical Biochemistry, Dept of Pharmacology, Dept of Pediatrics, Oslo University Hospital, Norway.<\/span>
\n
\nMULTIPLE MODEL OPTIMAL (MMOPT) SAMPLING FOR FIRST DOSE ORAL VORICONAZOLE TDM IN CHILDREN<\/span>
\nNeely MN<\/span>1<\/sup>, Bayard DS1<\/sup>, Hope WW2<\/sup>. 1<\/sup>Laboratory of Applied Pharmacokinetics, Children\u2019s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, USA. 2<\/sup>Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.<\/span>
\n
\nFREQUENCY OF ACHIEVING THE THERAPEUTIC RANGE WITH VANCOMYCIN IN INFANTS, CHILDREN AND ADOLESCENTS.<\/span>
\nConstance, J.E.<\/span>, Balch, A., Campbell, S.C., Stockmann, C., Sherwin, C.M.T., Spigarelli, M.G. Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. <\/span>
\n
\nESTIMATING FAT-FREE MASS IN CHILDREN.<\/span>
\nAl-Sallami HS<\/span>1<\/sup>, Goulding A2<\/sup>, Williams S2<\/sup>, Grant A2<\/sup>, Taylor R2<\/sup>, Duffull SB1<\/sup>. 1<\/sup>School of Pharmacy, University of Otago, Dunedin \u2013 New Zealand. 2<\/sup>School of Medicine, University of Otago, Dunedin \u2013 New Zealand.
\n
\nPEDIATRIC UNDERREPRESENTATION IN THERAPEUTIC DRUG MONITORING STUDIES.<\/span>
\nStockmann, C.<\/span>, Sherwin, C.M.T., Constance, J.E., Campbell, S.C, Linakis, M., Yu, T., Balch, A., Spigarelli, M.G. Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah.<\/span>
\n
\n1600-1700 WEDNESDAY AFTERNOON<\/span>
\n
\nHIGH-THROUGHPUT VALIDATED METHOD FOR THE QUANTIFICATION OF LACOSAMIDE IN SERUM USING ULTRA FAST SPE-MS\/MS.<\/span>
\nKorman E.<\/span>; Bjergum M.; Danso D.; Erbsen J.; Enger R.; Langman L. Ph.D; Jannetto P. Ph.D . Mayo Clinic Rochester, MN 55905 USA. <\/span>
\n
\nA UPLC-MS\/MS METHOD FOR THERAPEUTIC DRUG MONITORING OF ETONOGESTREL<\/span>
\nTiffany Thomas1<\/sup>, Kelsey Petrie2<\/sup>, Joonho Shim3<\/sup>, Kirsten M Abildskov1<\/sup>, Carolyn L Westhoff2<\/sup>, Serge Cremers<\/span>1<\/sup>. 1<\/sup>Irving Institute for Clinical and Translational Research, Columbia University Medical Center, New York, NY, USA. 2<\/sup>Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA. 3<\/sup>INHA University School of Medicine, Incheon, South Korea.<\/span>
\n
\nDEVELOPMENT OF A MASS SPECTROMETRIC IMMUNOASSAY FOR DIGOXIN.<\/span>
\nWilson R<\/span>1<\/sup>, Couchman L1<\/sup>, Krastins B2<\/sup>, Flanagan RJ1<\/sup>. 1<\/sup>King\u2019s College Hospital, London, SE5 9RS, UK. 2<\/sup>ThermoFisher Scientific BRIMS Center, Cambridge, MA, USA.<\/span>
\n
\nDETERMINATION OF RIVAROXABAN IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY \u2013TANDEM MASS SPECTROMETRY AND CORRELATION WITH CHROMOGENIC ASSAY.<\/span>
\nTamigniau A<\/span>1<\/sup>, Capron A1<\/sup>, Douxfils J2<\/sup>, Dogn\u00e9 JM2<\/sup>, Chatelain B3<\/sup>, Wallemacq P1<\/sup>. 1<\/sup>Laboratory of Clinical Chemistry, Saint-Luc University Hospital, Universit\u00e9 Catholique de Louvain, Brussels, Belgium\/2<\/sup>Departement of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Universit\u00e9 de Namur, Namur, Belgium\/3<\/sup>Hematology Laboratory, NTHC, NARILIS, CHU Mont-Godinne, Universit\u00e9 Catholique de Louvain, Mont-Godinne, Belgium.<\/span>
\n
\nTHERAPEUTIC DRUG MONITORING OF LEVETIRACETAM IN CLINICAL PRACTICE.<\/span>
\nSalvador-Garrido P<\/span>, Outeda-Mac\u00edas M, Mart\u00ednez-L\u00f3pez LM, Mart\u00edn-Herranz I.
\nPharmacy Service. University Hospital of A Coru\u00f1a. Xerencia de Xesti\u00f3n Integrada A Coru\u00f1a. A Coru\u00f1a. Spain.<\/span>
\n
\nPOPULATION PHARMACOKINETIC MODELING OF SUNITINIB WITH THE ABCG2<\/em> GENOTYPE IN PATIENTS WITH RENAL CELL CARCINOMA.<\/span>
\nMizuno T.<\/span>1,2<\/sup>, Fukuda T.1,6<\/sup>, Terada T.4<\/sup>, Fukudo M.2<\/sup>, Dong M.1<\/sup>, Kamba T.3<\/sup>, Yamasaki T.3<\/sup>, Ogawa O.3<\/sup>, Katsura T.2<\/sup>, Inui K.5<\/sup>, Vinks A.A.1,6<\/sup>. 1<\/sup>Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, USA. 2<\/sup>Department of Pharmacy, Kyoto University Hospital, Kyoto Japan. 3<\/sup>Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 4<\/sup>Department of Pharmacy, Shiga University of Medical Science Hospital, Otsu, Japan. 5<\/sup>Kyoto Pharmaceutical University, Kyoto, Japan. 6<\/sup>Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, USA.<\/span>
\n
\nPOPULATION PHARMACOKINETIC ANALYSIS OF DOCETAXEL AND SORAFENIB AND CHARACTERIZATION OF THEIR DRUG-DRUG INTERACTIONS WHEN CO-ADMINISTERED IN CHEMO-NA\u00cfVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.<\/sup>
\nFlora T Musuamba<\/span>1,2<\/sup>, Feby Mardjuadi3<\/sup>, Jean Pascal Machiels3<\/sup>, Pierre Wallemacq2<\/sup> and Roger K Verbeeck1<\/sup>. 1<\/sup>Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain, Brussels, Belgium. 2<\/sup>Louvain Centre for Toxicology and Applied Pharmacology, Universit\u00e9 catholique de Louvain, Brussels, Belgium. 3<\/sup>Service d\u2019oncologie m\u00e9dicale, Cliniques universitaires Saint-Luc, Institut de Recherche Exp\u00e9rimentale et Clinique (IREC, MIRO), Universit\u00e9 catholique de Louvain, Brussels, Belgium. <\/span><\/p>\n

GENOTYPE BASED DOSING MAY IMPROVE OUTCOMES AFTER BUSULFAN CONDITIONING.<\/spam>
\nBremer S<\/span>1<\/sup>, Fl\u00f8isand Y2<\/sup> and Bergan S3<\/sup>. 1<\/sup>Dept. of Medical Biochemistry, Oslo University Hospital, Norway. 2<\/sup>Dept. of Hematology, Oslo University Hospital, Norway. 3<\/sup>Dept. of Pharmacology, Oslo University Hospital, Norway.<\/span>
\n
\nUNRELIABILITY OF FIXED BUSULFAN DOSING SCHEDULE AND THE VITAL ROLE OF THERAPEUTIC DRUG MONITORING IN PAEDIATRIC HAEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT) CONDITIONING THERAPY.<\/span>
\n1<\/sup>Tesfaye H<\/span>, 1<\/sup>Branova R, 1<\/sup>Klapkova E, 1<\/sup>Prusa R., 2<\/sup>Janeckova D, 2<\/sup>Sedlacek P, 2<\/sup>Riha P, 2<\/sup>Keslov\u00e1 P, 2<\/sup>Krol L., 2<\/sup>Malis J., 2<\/sup>Sumerauer D., 2<\/sup>Sevec M.2<\/sup>. 1<\/sup>Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology, 2<\/sup>Department of Paediatric Haematology and Oncology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.<\/span>
\n
\nHIGH- THROUGHPUT VALIDATED METHOD FOR THE QUANTITAION OF BUSULFAN IN PLASMA USING ULTRA-FAST SPE-MS\/MS.<\/span>
\nDarlington Danso;<\/span> Matthew Bjergum; Robert Enger; Paul Jannetto Ph.D; Loralie Langman Ph.D. Mayo Clinic, Rochester, MN, Rochester, MN.<\/span>
\n
\nCYCLOSPORINE IN HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS: COMBINATION OF PHARMACOKINETIC TOOLS TO INCREASE THE RELIABILITY OF DOSE ADJUSTMENT.<\/br>
\nWoillard JB<\/span>1,2<\/sup>, Lebreton V1<\/sup>, Neely M3<\/sup>, Turlure P4<\/sup>, Giraut S4<\/sup>, Debord J1,2<\/sup>, Marquet P1,2<\/sup>, Saint-Marcoux F1,2<\/sup>. 1<\/sup>Pharmacology Department, CHU Limoges, France. 2<\/sup>INSERM UMR-S850, Univ Limoges, France. 3<\/sup>Laboratory of Applied Pharmacokinetics, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. 4<\/sup>Department of Hematology, CHU de Limoges, France.<\/span>
\n
\nNONPARAMETRIC APPROACH FOR POPULATION PHARMACOKINETIC STUDY OF TACROLIMUS IN HEART TRANSPLANT PATIENTS.<\/span>
\nYoudarene R1<\/sup>, Woillard JB<\/span>1,2<\/sup>, Fruit D1,2<\/sup>, Marquet P1,2<\/sup>, Saint-Marcoux F1,2<\/sup>. 1<\/sup>Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, France. 2<\/sup>INSERM UMR-S850, Univ Limoges, France.
\n
\nA NON-PARAMETRIC APPROACH TO DEVELOP A BAYESIAN ESTIMATOR FOR TACROLIMUS IN RENAL TRANSPLANT PATIENTS.<\/span>
\nBen Fredj N.1<\/sup>, Woillard J.B.2<\/sup>, Debord J.1<\/sup>, Chaabane A.1<\/sup>, Chadly Z.1<\/sup>, Ben Fadhel N.1<\/sup>, Boughattas N.1<\/sup>, Marquet P.2<\/sup>, Saint-marcoux F.2<\/sup>, Aouam K<\/span>1<\/sup>.1<\/sup>Department of Pharmacology, Monastir, Tunisia. 2<\/sup>Department of Pharmacology, Limoges University Hospital, France.<\/span>
\n
\nINDIVIDUAL DOSAGE OF DIGOXIN WITH CALCULATED AND MEASURED CONCENTRATION IN CONTEMPORARY MEDICINE.
\nZhao Li, Zhang Di, Zhang Xianglin.<\/span> Department of pharmacy, China-Japan friendship hospital, Beijing, 100029, China.<\/span>
\n
\nMONITORING OF PLASMA RIBAVIRIN \u2013 DATA FROM A TDM LABORATORY 2011 TO PRESENT.<\/span>
\nMorgan PE<\/span>1<\/sup>, Brown NW2<\/sup>, Barnabas A1<\/sup>, Agarwal K1<\/sup>, Tredger JM1,3<\/sup>. 1<\/sup>Institute of Liver Studies, King\u2019s College Hospital, London SE5 9RS, UK. 2<\/sup>Department of Clinical Chemistry, Wansbeck General Hospital, Ashington NE63 9JJ, UK. 3<\/sup>
\nKing\u2019s College London.<\/span>
\n
\nSIROLIMUS AND FK506 DIFFERENTLY MODULATE THE EXPRESSION OF PD-1 AND HVEM ON CD4+ REGULATORY T CELLS IN ALLO-RENAL RECIPIENTS.<\/span>
\nYangjuan Bai1<\/sup>, Yi Li1<\/sup>, Yunying Shi2<\/sup>, Yang Fu1<\/sup>, Bei Cai1<\/sup>, Yuangao Zou1<\/sup>, Lanlan Wang*1<\/sup>. 1<\/sup>Division of Clinical Immunology, Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R.China. 2<\/sup>Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, P.R.China. *Corresponding author.<\/span>
\n
\nINTEGRATED TARGETED QUANTITATION METHOD FOR INSULIN AND ITS THERAPEUTIC ANALOGS.<\/span>
\nEric Niederkofler<\/span>1<\/sup>, Dobrin Nedelkov1<\/sup>, Urban Kiernan1<\/sup>, David Phillips1<\/sup>, Kemmons Tubbss1<\/sup>, Scott Peterman2<\/sup>, Bryan Krastins2<\/sup>, Amol Prakash2<\/sup>, Mary Lopez2<\/sup>. 1<\/sup>Thermo Fisher Scientific, Tempe, AZ. 2<\/sup>Thermo Fisher Scientific BRIMS, Cambridge, MA.<\/span>
\n
\nTHERAPEUTIC MONITORING OF VANCOMYCIN IN NEONATES: IS THERE A COST TO NON-ADHERENCE OF GUIDELINES?<\/span>
\nFirth, S.D.<\/span>1<\/sup>, Yakub, S.Y.1<\/sup>, Sherwin, C.M.T.1<\/sup>, Korgenski, E.K.2<\/sup>, Constance, J.E.1<\/sup>, Balch, A.1<\/sup>, Spigarelli, M.G.1<\/sup>. 1<\/sup>Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. 2<\/sup>Intermountain Healthcare, Pediatric Clinical Program, University of Utah.<\/span>
\n
\nSEQUENTIAL PHARMACOKINETIC GANCYCLOVIR EXPOSURE AFTER LOW DOSE VALGANCYCLOVIR PROPHYLAXIS IN KIDNEY TRANSPLANT RECIPIENTS \u2013 AN INTERIM ANALYSIS.<\/span>
\nMathew BS<\/span>1<\/sup>, Basu G, Abraham AM2<\/sup>, Vijayakumar TS, Ratna Prabha1<\/sup>, Fleming DH1<\/sup>. 1<\/sup>Clinical Pharmacology Unit, Department of Nephrology, 2<\/sup>Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India.<\/span>
\n
\n1430-1530 THURSDAY AFTERNOON<\/span>
\n
\nDIRECT ANALYSIS OF 26 URINARY OPIOIDS AND METABOLITES BY MIXED-MODE \u00b5ELUTION SPE COMBINED WITH UPLC\/MS\/MS \u2013 IMPROVED PERFORMANCE VS. \u201cDILUTE-AND-SHOOT\u201d METHODOLOGY.<\/span>
\nDanaceau, J.<\/span>, Chambers, E., Fountain, K. Waters Corporation.<\/span>
\n
\nHIGH-THROUGHPUT AND SELECTIVE FORENSIC DRUG SCREENING IN URINE USING A SPE\/MS\/MS SYSTEM<\/span>
\nRomm M<\/span>, Schlicht K, Parikh N, Youssef M, Miller V, and LaMarr W. Agilent Technologies Inc., Wakefield, MA.<\/span>
\n
\nONE FOR ALL, ALL IN ONE: DETERMINATION OF GAMMA-HYDROXYBUTYRIC ACID IN BIOFLUIDS USING \u201cIN-VIAL\u201d DERIVATIZATION AND HEADSPACE-TRAP GAS CHROMATOGRAPHY-MASS SPECTROMETRY.<\/span>
\nIngels AS1,3<\/sup>, Neels H2<\/sup>, Lambert WE1<\/sup>, Stove CP<\/span>1<\/sup>. 1<\/sup>Laboratory of Toxicology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium; 2<\/sup>Laboratory of Toxicology, Antwerp University, Drie Eiken Campus, 2000 Antwerp, Belgium; 3<\/sup>Current address: Federal Public Service Justice, National Institute of Criminalistics and Criminology, Vilvoordsesteenweg 100, 1120 Brussels, Belgium. E-mail: christophe.stove@ugent.be<\/a>.<\/span>
\n
\nDETERMINATION OF THE TRICYCLIC ANTIDEPRESSANTS AMITRIPTYLINE, NORTRIPTYLINE, IMIPRAMINE, DESIPRAMINE, CLOMIPRAMINE AND DESMETHYLCLOMIPRAMINE IN DRIED BLOOD SPOTS USING LC-MS\/MS.<\/span>
\nE.J.J. Berm<\/span>1<\/sup>, J. Paardekooper2<\/sup>, E. Brummel-Mulder2<\/sup>, E.Hak3<\/sup>, B. Wilffert1<\/sup>, J.G. Maring2<\/sup>. 1<\/sup>Dept. of Pharmacy, section Pharmacotherapy and Pharmaceutical Care , University of Groningen, the Netherlands. 2<\/sup>Laboratory for Drug Analysis &Toxicology, Diaconessen Hospital Meppel& Bethesda Hospital Hoogeveen,the Netherlands. 3<\/sup>Dept. of Pharmacy, section PharmacoEpidemiology and PharmacoEconomics, University of Groningen, the Netherlands. <\/span>
\n
\nTHE EFFECTS OF UNBOUND MYCOPHENOLIC ACID (MPA) ON INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) INHIBITION IN PEDIATRIC KIDNEY TRANSPLANT PATIENTS.<\/span>
\nSmits T, BS<\/span>1<\/sup>, Cox S, BS1<\/sup>, Fukuda T, PhD1,2<\/sup>, Vinks A, PharmD, PhD1,2<\/sup>. 1<\/sup> Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA.
\n2<\/sup>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.<\/span>
\n
\nDEVELOPMENT OF A LC-MS\/MS METHOD TO DETERMINE MYCOPHENOLIC ACID CONCENTRATION IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS.<\/span>
\nMinh Thuan Nguyen Thi<\/span>, Arnaud Capron, Pierre Wallemacq. Universit\u00e9 catholique de Louvain, Louvain center for Toxicology and Applied Pharmacology (LTAP), Brussels.<\/span>
\n
\nABBREVIATED MPA-AUC IN LUNG TRANSPLANTATION IN COMPARISON WITH THE IMMUNE CELL RESPONSE.<\/span>
\nSch\u00fctz E<\/span>1<\/sup>, Warnecke G2<\/sup>, Fegbeutel C2<\/sup>, Haverich A2<\/sup>, Oellerich M3<\/sup>. 1<\/sup>Center of Molecular Diagnostics of IVM, University Goettingen, Goettingen, Germany. 2<\/sup>Department of Cardiothoracic, Transplantation and Vascular Surgery (HTTG), Hannover Medical School, Hannover, Germany. 3<\/sup>Department of Clinical Chemistry, University Medical Center Goettingen, Goettingen, Germany.<\/span>
\n
\nIMPACT OF RECIPIENT AND DONOR MULTIDRUG RESISTANCE PROTEIN 2 GENETIC VARIABILITY ON MYCOPHENOLIC ACID PHARMACOKINETICS FOLLOWING KIDNEY TRANSPLANTATION.<\/span>
\nMd Dom ZI<\/span>1,2<\/sup>, Coller JK2<\/sup>, Somogyi AA2<\/sup>, Sallustio BC1,2<\/sup>. 1<\/sup>Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville, SA; 2<\/sup>Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, SA, Australia.<\/span>
\n
\nPHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF MYCOPHENOLIC ACID: IMPROVED PREDICTION OF ABSORPTION AND ENTEROHEPATIC RECYCLING.<\/span>
\nRalf Stemkens, BSc1,2<\/sup>, Min Dong, PhD<\/span>1<\/sup>, Raja Venkatasubramanian, PhD1,3<\/sup>, Viera Lukacova, PhD4<\/sup>, Grazyna Fraczkiewicz, MSc4<\/sup>, Tsuyoshi Fukuda, PhD1,5<\/sup>, Alexander A. Vinks, PharmD, PhD1,5<\/sup>. 1<\/sup>Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA. 2<\/sup>Faculty of Pharmacy, University of Utrecht, Utrecht, Netherlands. 3<\/sup>Department of Anesthesia, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA. 4<\/sup>Simulations Plus, Inc., Lancaster, CA, USA. 5<\/sup>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.<\/span>
\n
\nMC4R rs489693: A CLINICAL RISK FACTOR FOR SECOND GENERATION ANTIPSYCHOTIC-RELATED WEIGHT GAIN.<\/span>
\nCzerwensky F1<\/sup>, Leucht S2<\/sup>, Steimer W<\/span>1<\/sup>. 1<\/sup>Institut f\u00fcr Klinische Chemie und Pathobiochemie and 2<\/sup>Klinik f\u00fcr Psychiatrie und Psychotherapie. Klinikum rechts der Isar der Technischen Universit\u00e4t M\u00fcnchen, Ismaninger Str. 22 81675 M\u00fcnchen.<\/span>
\n
\nTRANSPORTER GENETIC POLYMORPHISMS ASSOCIATED WITH VARIABLE MORPHINE PHARMACOKINETICS IN CHILDREN.<\/span>
\nFukuda T<\/span>1,3<\/sup>, Mizuno T1<\/sup>, Chidambaran V2,3<\/sup>, Venkatasubramanian R1,2<\/sup>, Ngamprasertwong P2,3<\/sup>, Niu J1,2<\/sup>, Esslinger H1<\/sup>, Vinks A1,3<\/sup>, Sadhasivam S2,3<\/sup>. 1<\/sup>Division of Clinical Pharmacology, 2<\/sup>Department of Anesthesia, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA. 3<\/sup>University of Cincinnati College of Medicine, Cincinnati, OH.<\/span>
\n
\nIMPACT OF CYP2C19<\/em> POLYMORPHISMS ON PHARMACOKINETICS AND PHARMACODYNAMICS OF LOW-DOSE CLOBAZAM THERAPY IN JAPANESE PATIENTS WITH EPILEPSY.<\/span>
\nSachiyo Hashi1<\/sup>, Mai Shibata2<\/sup>, Satohiro Masuda1<\/sup>, Kazuo Matsubara1<\/sup>, Masako Kinoshita3<\/sup>, Riki Matsumoto4<\/sup>, Akio Ikeda4<\/sup>, Ryosuke Takahashi4<\/sup>, Ikuko Yano1,2<\/sup>. 1<\/sup>Department of Pharmacy, Kyoto University Hospital, Kyoto, Japan. 2<\/sup>Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. 3<\/sup>Department of Neurology, Utano National Hospital, National Hospital Organization, Kyoto, Japan. 4<\/sup>Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.<\/span>
\n
\nIMPACT OF POR*28 ON THE CLINICAL PHARMACOKINETICS OF CYP3A PHENOTYPING PROBES MIDAZOLAM AND ERYTHROMYCIN.<\/span>
\nLaure Elens1,2<\/sup>, Annemieke J.M. Nieuweboer3<\/sup>, Stephen J. Clarke4<\/sup>, Kellie A. Charles5<\/sup>, Anne-Joy M. de Graan3<\/sup>, Vincent Haufroid2<\/sup>, Teun van Gelder6,7<\/sup>, Ron H.J. Mathijssen3<\/sup>, Ron H.N. van Schaik1<\/sup>. 1<\/sup>Depts of Clinical Chemistry, 3<\/sup>Medical Oncology, 6<\/sup>Internal Medicine and 7<\/sup>Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands, 2<\/sup>Louvain centre for Toxicology and Applied Pharmacology (LTAP), Universit\u00e9 catholique de Louvain, Brussels, Belgium, 4<\/sup>Dicipline of Medicine, Sydney Medical School-Northern, University of Sydney, NSW, Australia and 5<\/sup>Discipline of Pharmacology, School of Medical Sciences and Bosch Institute, University of Sydney, NSW, Australia. <\/span>
\n
\nDIMETHOCAINE, A SYNTHETIC COCAINE DERIVATIVE: STUDIES ON ITS IN VIVO AND IN VITRO METABOLISM AND ITS DETECTABILITY IN URINE.<\/span>
\nMeyer MR<\/span>, Lindauer C, Welter J, and Maurer HH. Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar).<\/span>
\n
\n11-Nor-9-CARBOXY-\u22069-TETRAHYDROCANNABINOL QUANTIFICATION IN HUMAN ORAL FLUID BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY<\/span>
\nScheidweiler KB<\/span>1<\/sup>, Himes SK1<\/sup>, Chen X2<\/sup>, Liu HF2<\/sup>, and Huestis MA1<\/sup>. 1<\/sup> Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA. 2<\/sup>ABSciex 353 Hatch Drive, Foster City, CA 94404, USA.<\/span>
\n
\nDEVELOPMENT OF A NOVEL TURBULENT FLOW CHROMATOGRAPHY MODE TO BE USED FOR FULLY AUTOMATED METABOLITE-BASED URINE SCREENING APPROACH USING AN LC-Q-EXACTIVE EQUIPMENT
\nHelfer AG<\/span>, Meyer MR, Michely JA, Maurer HH. Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany.<\/span>
\n
\nADAPTATION OF URINE AND ORAL FLUID CEDIA IMMUNOASSAY TESTS FOR THE ANALYSIS OF RECREATIONAL DRUGS IN SERUM ON THE THERMO SCIENTIFIC INDIKO PLUS.<\/span>
\nDe Sloovere M.M.W.<\/span>, Stove V., Hollebosch M., Van Caeneghem E.,Verstraete A.G. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.<\/span>
\n
\nIn Vitro<\/em> CYTOCHROME P450 INHIBITION COCKTAIL ASSAY \u2013 PART II: DEVELOPMENT OF AN ALL-IN-ONE COCKTAIL APPROACH: DREAM OR REALITY?<\/span>
\nDinger J<\/span>, Meyer MR, and Maurer HH. Department of Experimental and Clinical Toxicology, Saarland University, Homburg (Saar), Germany.<\/span>
<\/p>\n","protected":false},"excerpt":{"rendered":"

1400-1500 MONDAY AFTERNOON EFFECT OF THE CYP3A5 6986A>G POLYMORPHISM ON TACROLIMUS PHARMACOKINETICS IN LIVER TRANSPLANT RECIPIENTS: A META-ANALYSIS Buendia JA1, Bramuglia G2,Staatz CE3. 1Pharmacology and Toxicology Department. Faculty of Medicine. University of Antioquia, Colombia. Email: Jefferson.buendia@gmail.com. 2Faculty of Pharmacy and … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"open","template":"","meta":[],"_links":{"self":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages\/643"}],"collection":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/iatdmct.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=643"}],"version-history":[{"count":99,"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages\/643\/revisions"}],"predecessor-version":[{"id":1309,"href":"http:\/\/iatdmct.com\/index.php?rest_route=\/wp\/v2\/pages\/643\/revisions\/1309"}],"wp:attachment":[{"href":"http:\/\/iatdmct.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}